Brief: Revive Therapeutics Provides Update On FDA Phase 3 Clinical Trial For Bucillamine In Covid-19
24/03/2021 12:38
March 24 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON FDA PHASE 3
CLINICAL
TRIAL FOR BUCILLAMINE IN COVID-19
* REVIVE THERAPEUTICS LTD - ON TRACK TO MEET ITS PLANNED
ENROLLMENT GOAL FOR STUDY IN Q2-2021
* REVIVE THERAPEUTICS LTD - TO DATE, THERE HAVE BEEN NO
SERIOUS
ADVERSE EVENTS OR SAFETY CONCERNS IN STUDY
Source text for Eikon: ID:nGNX7kYYk5
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure